Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436055 · ClinicalTrials.gov registry record
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
A clinical trial, sponsored by Duke University.
- Terminated
- Registry status
- 92
- Enrollment target
NCT04436055: Clinical Trial study, sponsored by Duke University.
NCT04436055 is a clinical trial that was terminated before completion, run by Duke University. The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04436055 was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- 92 participants
- Enrollment target
Study Summary
The overall objective of this proposed project is to prospectively evaluate the epigenetic and developmental effects of paternal cannabis and other drug use in offspring.
Primary Outcome
Examine methylation profiles from fathers with varying patterns of drug use as well as from fathers with no drug use; and determine whether methylation profiles are transmitted to offspring.
Interventions
- OTHER No Intervention will be used
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2022-07-01 |
Why NCT04436055 stopped before completion
NCT04436055 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 92 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No Intervention will be used is the first listed.
NCT04436055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04436055 about?
NCT04436055 is a clinical study titled "Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)". The overall objective of this proposed project is to prospectively evaluate the epigenetic and developmental effects of paternal cannabis and other drug use in offspring.
What is the current status of trial NCT04436055?
This trial is currently terminated. The enrollment target is 92 participants. The study started on 2020-10-26. Estimated completion is 2022-07-01.
What interventions are being tested in trial NCT04436055?
The interventions under investigation include: No Intervention will be used (OTHER).
Who is sponsoring clinical trial NCT04436055?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI